ECO Animal Health Group (LON:EAH) Receives Buy Rating from Shore Capital

Shore Capital restated their buy rating on shares of ECO Animal Health Group (LON:EAH) in a report released on Friday morning, Marketbeat Ratings reports.

ECO Animal Health Group Price Performance

The company has a 50-day moving average of GBX 74.68 and a two-hundred day moving average of GBX 101.87. The firm has a market capitalization of £48.27 million, a P/E ratio of 3,740.00 and a beta of -0.05. ECO Animal Health Group has a 12 month low of GBX 60 ($0.76) and a 12 month high of GBX 135 ($1.72). The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.31.

About ECO Animal Health Group

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, mange, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle.